Need help finding what you are looking for?
Contact Us
PUBLISHER: DelveInsight | PRODUCT CODE: 2082763
PUBLISHER: DelveInsight | PRODUCT CODE: 2082763
Non-metastatic Prostate Cancer (nmPC) - Epidemiology Forecast - 2036
PUBLISHED:
PAGES: 115 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Non-metastatic Prostate Cancer (nmPC) Insights and Trends
- Prostate cancer happens when abnormal cells form and grow in the prostate gland. Unlike benign (or non-cancerous) growths, these growths are cancerous (malignant). Prostate cancer can be life-threatening if it becomes "metastatic" and spreads beyond the prostate. Early stages of prostate cancer rely on testosterone to grow; sometimes, lowering testosterone can control growth.
- Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. If prostate cancer is diagnosed as CRPC, it can grow or spread even with low testosterone levels, and with non-metastatic CRPC (nmCRPC), the cancer no longer responds to hormone treatment. It shows signs of growth, like a rising PSA (prostate-specific antigen) level, but it is only found in the prostate and has not spread.
- Often, there are no symptoms for patients with nmCRPC. Most men cannot tell if the cancer is growing unless the doctor notices a rise in the PSA level. Changes are tracked with blood tests, physical exams, and scans, such as CT, bone, and PET scans.
- Approximately one in nine men in the US is diagnosed with this disease at some point. As per the American Cancer Society, 2019, prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.
DelveInsight's 'Non-metastatic Prostate Cancer (nmPC) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the Non-metastatic Prostate Cancer (nmPC), historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Non-metastatic Prostate Cancer Understanding and Diagnosis Algorithm
Non-metastatic Prostate Cancer (nmPC) Overview
Non-metastatic prostate cancer is confined to the prostate or nearby tissues, without distant spread. It's often asymptomatic and detected via elevated PSA or abnormal DRE. Diagnosis is confirmed by biopsy, with imaging used to assess local spread. Risk is stratified by PSA, Gleason score, and tumor stage, guiding treatment options like active surveillance, surgery, or radiation. Early detection generally leads to a favorable prognosis.
Non-metastatic Prostate Cancer (nmPC) Diagnosis
Diagnosis of Non-metastatic Prostate Cancer is based on a combination of clinical evaluation and diagnostic testing. It is typically suspected in men with elevated prostate-specific antigen (PSA) levels or abnormal findings on digital rectal examination (DRE). Confirmation is achieved through a prostate biopsy, which determines tumor grade and aggressiveness. Imaging techniques such as multiparametric MRI are used to assess local tumor extent, while CT scans or bone scans help rule out distant metastasis, ensuring accurate staging and appropriate treatment planning.
Non-metastatic Prostate Cancer Epidemiology
Key Findings from Non-metastatic Prostate Cancer (nmPC) Epidemiological Analysis and Forecast
- Approximately one in nine men in the US is diagnosed with this disease at some point. As per the American Cancer Society, 2019, prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.
- The majority of prostate cancer cases are diagnosed before distant spread, with approximately 70% of cases identified at a localized (non-metastatic) stage in the United States, reflecting the impact of early detection and PSA-based screening.
Scope of the Report:
- The report covers a segment of an executive summary, a descriptive overview of nmPC, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Non-metastatic Prostate Cancer(nmPC) Patient Population Forecast
Report Key Strengths
- Epidemiology-based (epi-based) Bottom-up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs:
- What are the disease risks, burdens, and unmet needs of nmPC? What will be the growth opportunities across the 7MM concerning the patient population with nmPC?
- What is the historical and forecasted Ewing sarcoma patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Product Code: DIEI1840
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Non-metastatic Prostate Cancer (nmPC)
5. Epidemiology Forecast Methodology
4. Non-metastatic Prostate Cancer (nmPC) Epidemiology Overview at a Glance
- 4.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
- 4.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
5. Non-metastatic Prostate Cancer (nmPC) Disease Background and Overview
- 5.1. Introduction
- 5.2. Symptom
- 5.3. Transmission and Risk Factors
- 5.4. Pathophysiology
- 5.5. Diagnosis and Screening
- 5.5.1. Diagnostic Algorithm
- 5.5.2. Diagnosis Guidelines
6. Non-metastatic Prostate Cancer (nmPC) Epidemiology and Patient Population
- 6.1. Key Findings
- 6.2. Assumptions and Rationale
- 6.3. Total Diagnosed Prevalent Cases of Non-metastatic Prostate Cancer (nmPC) in the 7MM
- 6.4. The United States
- 6.4.1. Total Diagnosed Prevalent Cases of nmPC in the United States
- 6.4.2. Age-specific Diagnosed Prevalent Cases of nmPC in the United States
- 6.4.3. Stage-specific Diagnosed Prevalent Cases of nmPC in the United States
- 6.4.4. Total Line-wise Treated Cases of nmPC in the United States
- 6.5. EU4 and the UK
- 6.5.1. Total Diagnosed Prevalent Cases of nmPC in EU4 and the UK
- 6.5.2. Age-specific Diagnosed Prevalent Cases of nmPC in EU4 and the UK
- 6.5.3. Stage-specific Diagnosed Prevalent Cases of nmPC in EU4 and the UK
- 6.5.4. Total Line-wise Treated Cases of nmPC in EU4 and the UK
- 6.6. Japan
- 6.6.1. Total Diagnosed Prevalent Cases of nmPC in Japan
- 6.6.2. Age-specific Diagnosed Prevalent Cases of nmPC in Japan
- 6.6.3. Stage-specific Diagnosed Prevalent Cases of nmPC in Japan
- 6.6.4. Total Line-wise Treated Cases of nmPC in Japan
7. Appendix
- 7.1. Bibliography
- 7.2. Report Methodology
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight
Product Code: DIEI1840
List of Tables
- Table 1: Summary of nmPC Epidemiology (2025-2036)
- Table 2: nmPC Epidemiology
- Table 3: Total Diagnosed Prevalent Cases of nmPC in the United States (2022-2036)
- Table 4: Age-specific Diagnosed Prevalent Cases of nmPC in the United States (2022-2036)
- Table 5: Stage-specific Diagnosed Prevalent Cases of nmPC in the United States (2022-2036)
- Table 6: Total Line-wise Treated Cases of nmPC in the United States(2022-2036)
- Table 7: Total Diagnosed Prevalent Cases of nmPC in EU4 and the UK (2022-2036)
- Table 8: Age-specific Diagnosed Prevalent Cases of nmPC in EU4 and the UK (2022-2036)
- Table 9: Stage-specific Diagnosed Prevalent Cases of nmPC in EU4 and the UK (2022-2036)
- Table 10: Total Line-wise Treated Cases of nmPC in EU4 and the UK (2022-2036)
- Table 11: Total Diagnosed Prevalent Cases of nmPC in Japan(2022-2036)
- Table 12: Age-specific Diagnosed Prevalent Cases of nmPC in Japan(2022-2036)
- Table 13: Stage-specific Diagnosed Prevalent Cases of nmPC in Japan (2022-2036)
- Table 14: Total Line-wise Treated Cases of nmPC in Japan (2022-2036)
List of Figures
- Figure 1: Summary of nmPC Epidemiology (2025-2036)
- Figure 2: NmPC Epidemiology
- Figure 3: Total Diagnosed Prevalent Cases of nmPC in the United States (2022-2036)
- Figure 4: Age-specific Diagnosed Prevalent Cases of nmPC in the United States (2022-2036)
- Figure 5: Stage-specific Diagnosed Prevalent Cases of nmPC in the United States (2022-2036)
- Figure 6: Total Line-wise Treated Cases of nmPC in the United States(2022-2036)
- Figure 7: Total Diagnosed Prevalent Cases of nmPC in EU4 and the UK (2022-2036)
- Figure 8: Age-specific Diagnosed Prevalent Cases of nmPC in EU4 and the UK (2022-2036)
- Figure 9: Stage-specific Diagnosed Prevalent Cases of nmPC in EU4 and the UK (2022-2036)
- Figure 10: Total Line-wise Treated Cases of nmPC in EU4 and the UK (2022-2036)
- Figure 11: Total Diagnosed Prevalent Cases of nmPC in Japan(2022-2036)
- Figure 12: Age-specific Diagnosed Prevalent Cases of nmPC in Japan(2022-2036)
- Figure 13: Stage-specific Diagnosed Prevalent Cases of nmPC in Japan (2022-2036)
- Figure 14: Total Line-wise Treated Cases of nmPC in Japan (2022-2036)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.